DOD Inspector General Issues Report on Defense Health Agency Controls Over High-Risk Pharmaceutical Payments
November 20, 2017
November 20, 2017
WASHINGTON, Nov. 21 -- The U.S. Department of Defense Office of the Inspector General issued the following report:
Objective
We determined whether the Defense Health Agency (DHA) developed controls to identify health care pharmaceutical payments at high risk of fraud or abuse. We focused on controls to prevent and detect potentially fraudulent or abusive claims for pharmaceuticals. The DHA defines "abuse" as any practice that is inconsistent with accepted prac . . .
Objective
We determined whether the Defense Health Agency (DHA) developed controls to identify health care pharmaceutical payments at high risk of fraud or abuse. We focused on controls to prevent and detect potentially fraudulent or abusive claims for pharmaceuticals. The DHA defines "abuse" as any practice that is inconsistent with accepted prac . . .